Jamaican scientist, Dr. Henry Lowe, says he’s moving to have a drug he developed to treat myeloid leukaemia, enter the market in another two to three years.
The drug, called Cresorol, was developed from cannabis.
It’s been recognised by the United States Food and Drug Administration, FDA, which has granted it orphan-drug designation status.
It’s said to be the first of its kind to be developed in any developing country.
The Orphan Drug Act, ODA provides for the granting of ‘special status’ to a drug which treats a rare disease or condition, upon request of a sponsor.
For a drug to qualify for orphan designation status, both the drug and the disease or condition must meet certain criteria specified in the Act.
News emerged this week that the FDA has granted the drug orphan-drug designation status.
Dr. Lowe is celebrating the development.
Creserol is being estimated to have annual minimum sales of more than 2-hundred-and-50 million US dollars in the US market alone.
Dr. Lowe says he intends to seek partnerships to allow the drug to enter the market.